We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...

The Nordic region accounts for about 1 per cent of the world’s gross domestic product and 0.3 per cent of its population. Yet ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

Imagine if you could eat your fill on Christmas day then dial down your appetite for January. Good news: such a prospect may ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

Diabetes drugs now represent over 75% of total sales in the metabolic disorders market, up from below 40% ten years ago. The ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...